These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 19667604)

  • 41. [The COMET study compares effect of two different beta-blockers in chronic heart failure. Carvedilol better than metoprolol].
    Swedberg K
    Lakartidningen; 2003 Sep; 100(37):2852-4. PubMed ID: 14558169
    [No Abstract]   [Full Text] [Related]  

  • 42. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.
    Wali RK; Iyengar M; Beck GJ; Chartyan DM; Chonchol M; Lukas MA; Cooper C; Himmelfarb J; Weir MR; Berl T; Henrich WL; Cheung AK
    Circ Heart Fail; 2011 Jan; 4(1):18-26. PubMed ID: 21036889
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influence of global region on outcomes in heart failure β-blocker trials.
    O'Connor CM; Fiuzat M; Swedberg K; Caron M; Koch B; Carson PE; Gattis-Stough W; Davis GW; Bristow MR
    J Am Coll Cardiol; 2011 Aug; 58(9):915-22. PubMed ID: 21851879
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The use of beta blockers in heart failure: clinical studies].
    Cobelli F
    Ital Heart J Suppl; 2000 Aug; 1(8):996-1002. PubMed ID: 10993005
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of outcomes and usefulness of carvedilol across a spectrum of left ventricular ejection fractions in patients with heart failure in clinical practice.
    Massie BM; Nelson JJ; Lukas MA; Greenberg B; Fowler MB; Gilbert EM; Abraham WT; Lottes SR; Franciosa JA;
    Am J Cardiol; 2007 May; 99(9):1263-8. PubMed ID: 17478155
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Death and hospitalization in heart failure patients receiving carvedilol vs. metoprolol tartrate.
    Delea TE; Stanford R; Hagiwara M; Edelsberg JS; Oster G
    Int J Cardiol; 2005 Mar; 99(1):117-24. PubMed ID: 15721509
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rationale, design, and organization of the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF). The International Steering Committee.
    Am J Cardiol; 1997 Nov; 80(9B):54J-58J. PubMed ID: 9375952
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Hormonal hyperactivity in heart failure. Differences in beta blockers].
    Beuckelmann DJ
    Herz; 2002 Aug; 27 Suppl 1():9-15. PubMed ID: 12229258
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of carvedilol and metoprolol on the mode of death in patients with heart failure.
    Remme WJ; Cleland JG; Erhardt L; Spark P; Torp-Pedersen C; Metra M; Komajda M; Moullet C; Lukas MA; Poole-Wilson P; Di Lenarda A; Swedberg K
    Eur J Heart Fail; 2007 Nov; 9(11):1128-35. PubMed ID: 17716943
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [A randomized comparison of carvedilol and metoprolol in patients with chronic heart failure. The Carvedilol Or Metoprolol European Trial (COMET) ].
    Torp-Pedersen CT;
    Ugeskr Laeger; 2004 Aug; 166(32):2671-4. PubMed ID: 15347171
    [No Abstract]   [Full Text] [Related]  

  • 51. Critical differences among beta-adrenoreceptor antagonists in myocardial failure: debating the MERIT of COMET.
    McBride BF; White CM
    J Clin Pharmacol; 2005 Jan; 45(1):6-24. PubMed ID: 15601801
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Drug therapy of chronic heart failure: when are beta receptor blockers indicated?].
    vom Dahl J; Schotten U; Sasse A
    Dtsch Med Wochenschr; 1999 Sep; 124 Suppl 2():S48-53. PubMed ID: 10535047
    [No Abstract]   [Full Text] [Related]  

  • 53. Meta-analysis of the effects of carvedilol versus metoprolol on all-cause mortality and hospitalizations in patients with heart failure.
    Briasoulis A; Palla M; Afonso L
    Am J Cardiol; 2015 Apr; 115(8):1111-5. PubMed ID: 25708861
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Early initiation of beta blockade in heart failure: issues and evidence.
    Williams RE
    J Clin Hypertens (Greenwich); 2005 Sep; 7(9):520-8; quiz 529-30. PubMed ID: 16227771
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The importance of beta blockers in the treatment of heart failure.
    Chavey WE
    Am Fam Physician; 2000 Dec; 62(11):2453-62. PubMed ID: 11130231
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Beta-blockers in the treatment of chronic heart failure. How should results of clinical studies be introduced into clinical practice].
    Vítovec J; Spinar J
    Vnitr Lek; 2000 Mar; 46(3):161-5. PubMed ID: 11048519
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Meta-analysis of effect of beta-blocker therapy on mortality in patients with New York Heart Association class IV chronic congestive heart failure.
    Whorlow SL; Krum H
    Am J Cardiol; 2000 Oct; 86(8):886-9. PubMed ID: 11024409
    [No Abstract]   [Full Text] [Related]  

  • 58. Evaluating the effectiveness of different beta-adrenoceptor blockers in heart failure patients.
    Lin TY; Chen CY; Huang YB
    Int J Cardiol; 2017 Mar; 230():378-383. PubMed ID: 28041715
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure.
    De Freitas O; Lenz O; Fornoni A; Materson BJ
    Vasc Health Risk Manag; 2006; 2(2):139-44. PubMed ID: 17319457
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trial.
    Packer M
    J Card Fail; 2003 Dec; 9(6):429-43. PubMed ID: 14966782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.